🕵️ Vanda Pharmaceuticals Inc. ($VNDA)
SEC insider & ownership activity, last 12 months · CIK 1347178 · every row links its SEC filing
Over the last 12 months insiders sold $2.8M against $42K of open-market buying. Mihael H. Polymeropoulos sold $1.3M in discretionary trades (Aug–Mar). Blackrock, Inc. trimmed 15.6% → 8.1%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $42K (1 lots) · 6 sellers, $2.8M (6 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Mihael H. Polymeropoulos | 1 | $42K | 1 | $1.3M | Mar 2, 2026 |
| Kevin Moran | 0 | – | 1 | $351K | Mar 2, 2026 |
| Timothy Williams | 0 | – | 1 | $351K | Mar 2, 2026 |
| Gunther Birznieks | 0 | – | 1 | $351K | Mar 2, 2026 |
| Joakim Wijkstrom | 0 | – | 1 | $255K | Mar 2, 2026 |
| Honore Tage | 0 | – | 1 | $241K | Feb 23, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Blackrock, Inc. | 8.1% | 13G | Feb 7, 2025 | filing ↗ | |
| State Street Corporation | 5.1% | 13G | May 12, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Timothy Williams | $351K | Mar 2, 2026 | filing ↗ |
| Gunther Birznieks | $351K | Mar 2, 2026 | filing ↗ |
| Joakim Wijkstrom | $255K | Mar 2, 2026 | filing ↗ |
| Mihael H. Polymeropoulos | $1.3M | Mar 2, 2026 | filing ↗ |
| Kevin Moran | $351K | Mar 2, 2026 | filing ↗ |
| Honore Tage | $241K | Feb 23, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Shareholder vote (5.07) | Jun 4, 2026 | filing ↗ |
| Earnings (2.02) | May 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 6, 2026 | filing ↗ |
| Officer/director changes (5.02) | Apr 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 22, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 29, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 10, 2026 | filing ↗ |
| Other events (8.01) | Feb 20, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 20, 2026 | filing ↗ |
| Officer/director changes (5.02) | Feb 18, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 18, 2026 | filing ↗ |
| Earnings (2.02) | Feb 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 11, 2026 | filing ↗ |
| Other events (8.01) | Jan 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 7, 2026 | filing ↗ |
| Other events (8.01) | Dec 30, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 30, 2025 | filing ↗ |
| Other events (8.01) | Dec 4, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 4, 2025 | filing ↗ |
| Other events (8.01) | Nov 28, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 28, 2025 | filing ↗ |
| Earnings (2.02) | Oct 29, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 29, 2025 | filing ↗ |
| Other events (8.01) | Oct 1, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 1, 2025 | filing ↗ |
| Earnings (2.02) | Jul 31, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 31, 2025 | filing ↗ |